AstraZeneca’s 25-year milestone
AstraZeneca is celebrating the 25th anniversary of the merger of Swedish Astra AB and UK-based Zeneca Group PLC in 1999. The merger catalysed the company’s growth into a global leader in pharmaceuticals and biotechnology. AstraZeneca in Ireland celebrated this landmark occasion at its Blanchardstown headquarters with a panel discussion focusing on the company’s future growth and developments. Speakers included Alex Wilkes, Country President, AstraZeneca Ireland Marketing Company; Ruth March, Senior Vice President, Precision Medicine; Shane Doyle, Senior Vice President, Head of Operations & Sustainability for Alexion, AstraZeneca Rare Disease Unit and Jon-Paul Sherlock, API Commercialisation Site Lead.
Speaking at the event, Alex Wilkes said: “As we reflect on the past 25 years since the AstraZeneca merger, we celebrate innovation and excellence in science that resonates across the globe. I am immensely proud of the role our Irish operations play in our global success. The commitment, expertise, and innovative spirit of our team in Ireland are instrumental in driving our mission forward. Here’s to celebrating our achievements, and the brighter horizons that lie ahead as we continue to forge the path of medical breakthroughs and transforming patient care for people society and planet.”
In the last quarter of the century, AstraZeneca has effectively harnessed science to develop ground-breaking treatments in areas including oncology, immunology, renal and metabolic diseases, and respiratory and cardiac health. In Ireland AstraZeneca and Alexion, AstraZeneca Rare Disease, employs over 1,200 people across two sites in Dublin and Athlone. AstraZeneca in Ireland provides medicines that treat more than 200,000 patients.
Globally AstraZeneca now employs over 83,000 people in 16 countries delivering therapies to patients in 130 countries worldwide
CAPTION:
Pictured are: Alex Wilkes, Country President, AstraZeneca Ireland Marketing Company; Ruth March, Senior Vice President, Precision Medicine; Jon-Paul Sherlock, API Commercialisation Site Lead and Shane Doyle, Senior Vice President, Head of Operations & Sustainability for Alexion, AstraZeneca Rare Disease Unit.
